Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs. 806.55, up by 14.25 points or 1.80% from its previous closing of Rs. 792.30 on the BSE.

The scrip opened at Rs. 811.00 and has touched a high and low of Rs. 812.10 and Rs. 800.50 respectively. So far 25319 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 877.40 on 03-Sep-2014 and a 52 week low of Rs. 535.55 on 18-Sep-2013.

Last one week high and low of the scrip stood at Rs. 853.00 and Rs. 786.50 respectively. The current market cap of the company is Rs. 164098.32 crore.

The promoters holding in the company stood at 63.65% while Institutions and Non-Institutions held 28.05% and 8.29% respectively.

Sun Pharmaceutical Industries and Merck & Co., Inc. through their respective subsidiaries, have entered into an exclusive worldwide licensing agreement for Merck’s investigational therapeutic antibody candidate, tildrakizumab, (MK-3222), which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis, a skin ailment.

Under terms of the agreement, Sun Pharma will acquire worldwide rights to tildrakizumab for use in all human indications from Merck in exchange for an upfront payment of $80 million. Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma.

Upon product approval, Sun Pharma will be responsible for regulatory activities, including subsequent submissions, pharmacovigilance, post approval studies, manufacturing and commercialization of the approved product. Merck is eligible to receive undisclosed payments associated with regulatory (including product approval) and sales milestones, as well as tiered royalties ranging from mid-single digit through teen percentage rates on sales.

The above transaction is however subject to customary closing conditions, including the requirements under the Hart Scott-Rodino Antitrust Improvements Act.